Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of$ 0.35. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.43 per share when it actually produced a loss of $0.39, delivering a surprise of 9.30%. Over the last four quarters ...